U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Astrocytosis

MedGen UID:
854483
Concept ID:
C3887640
Pathologic Function
Synonyms: Astrocytoses; Astrogliosis
SNOMED CT: Astrocytic cell proliferation (81415000)
 
HPO: HP:0002446

Definition

Proliferation of astrocytes in the area of a lesion of the central nervous system. [from HPO]

Term Hierarchy

Conditions with this feature

Progressive sclerosing poliodystrophy
MedGen UID:
60012
Concept ID:
C0205710
Disease or Syndrome
POLG-related disorders comprise a continuum of overlapping phenotypes that were clinically defined long before their molecular basis was known. Most affected individuals have some, but not all, of the features of a given phenotype; nonetheless, the following nomenclature can assist the clinician in diagnosis and management. Onset of the POLG-related disorders ranges from infancy to late adulthood. Alpers-Huttenlocher syndrome (AHS), one of the most severe phenotypes, is characterized by childhood-onset progressive and ultimately severe encephalopathy with intractable epilepsy and hepatic failure. Childhood myocerebrohepatopathy spectrum (MCHS) presents between the first few months of life and about age three years with developmental delay or dementia, lactic acidosis, and a myopathy with failure to thrive. Other findings can include liver failure, renal tubular acidosis, pancreatitis, cyclic vomiting, and hearing loss. Myoclonic epilepsy myopathy sensory ataxia (MEMSA) now describes the spectrum of disorders with epilepsy, myopathy, and ataxia without ophthalmoplegia. MEMSA now includes the disorders previously described as spinocerebellar ataxia with epilepsy (SCAE). The ataxia neuropathy spectrum (ANS) includes the phenotypes previously referred to as mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO). About 90% of persons in the ANS have ataxia and neuropathy as core features. Approximately two thirds develop seizures and almost one half develop ophthalmoplegia; clinical myopathy is rare. Autosomal recessive progressive external ophthalmoplegia (arPEO) is characterized by progressive weakness of the extraocular eye muscles resulting in ptosis and ophthalmoparesis (or paresis of the extraocular muscles) without associated systemic involvement; however, caution is advised because many individuals with apparently isolated arPEO at the onset develop other manifestations of POLG-related disorders over years or decades. Of note, in the ANS spectrum the neuropathy commonly precedes the onset of PEO by years to decades. Autosomal dominant progressive external ophthalmoplegia (adPEO) typically includes a generalized myopathy and often variable degrees of sensorineural hearing loss, axonal neuropathy, ataxia, depression, parkinsonism, hypogonadism, and cataracts (in what has been called "chronic progressive external ophthalmoplegia plus," or "CPEO+").
Frontotemporal dementia and/or amyotrophic lateral sclerosis 7
MedGen UID:
318833
Concept ID:
C1833296
Disease or Syndrome
CHMP2B frontotemporal dementia (CHMP2B-FTD) has been described in a single family from Denmark, in one individual with familial FTD from Belgium, and in one individual with FTD and no family history. It typically starts between ages 46 and 65 years with subtle personality changes and slowly progressive behavioral changes, dysexecutive syndrome, dyscalculia, and language disturbances. Disinhibition or loss of initiative is the most common presenting symptom. The disease progresses over a few years into profound dementia with extrapyramidal symptoms and mutism. Several individuals have developed an asymmetric akinetic rigid syndrome with arm and gait dystonia and pyramidal signs that may be related to treatment with neuroleptic drugs. Symptoms and disease course are highly variable. Disease duration may be as short as three years or longer than 20 years.
Isolated focal cortical dysplasia type II
MedGen UID:
339510
Concept ID:
C1846385
Congenital Abnormality
Focal cortical dysplasia type II (FCORD2), or focal cortical dysplasia of Taylor (FCDT), is a cerebral developmental malformation that results in a clinical phenotype of intractable epilepsy, usually requiring surgery. FCORD2 has been classified histologically into 2 subtypes: a type without balloon cells, known as type IIA, and a type with balloon cells, known as type IIB (Palmini et al., 2004). Affected individuals have refractory seizures, usually with onset in early childhood, and may have persistent intellectual disability. Most patients require neurosurgical resection of affected brain tissue to ameliorate seizure frequency and severity (summary by Moller et al., 2016).
Polyhydramnios, megalencephaly, and symptomatic epilepsy
MedGen UID:
370203
Concept ID:
C1970203
Disease or Syndrome
A rare genetic neurological disorder with characteristics of pregnancy complicated by polyhydramnios, severe intractable epilepsy presenting in infancy, severe hypotonia, decreased muscle mass, global developmental delay, craniofacial dysmorphism (long face, large forehead, peaked eyebrows, broad nasal bridge, hypertelorism, large mouth with thick lips), and macrocephaly due to megalencephaly and hydrocephalus in most patients. Additional features that have been reported include cardiac anomalies like atrial septal defects, diabetes insipidus and nephrocalcinosis among others.
Supranuclear palsy, progressive, 1
MedGen UID:
1640811
Concept ID:
C4551863
Disease or Syndrome
The spectrum of clinical manifestations of MAPT-related frontotemporal dementia (MAPT-FTD) has expanded from its original description of frontotemporal dementia and parkinsonian manifestations to include changes in behavior, motor function, memory, and/or language. A recent retrospective study suggested that the majority of affected individuals have either behavioral changes consistent with a diagnosis of behavioral variant FTD (bvFTD) or, less commonly, a parkinsonian syndrome (i.e., progressive supranuclear palsy, corticobasal syndrome, or Parkinson disease). Fewer than 5% of people with MAPT-FTD have primary progressive aphasia or Alzheimer disease. Clinical presentation may differ between and within families with the same MAPT variant. MAPT-FTD is a progressive disorder that commonly ends with a relatively global dementia in which some affected individuals become mute. Progression of motor impairment in affected individuals results in some becoming chairbound and others bedbound. Mean disease duration is 9.3 (SD: 6.4) years but is individually variable and can be more than 30 years in some instances.

Professional guidelines

PubMed

Pusateri A, Margo CE
Arch Pathol Lab Med 2014 Sep;138(9):1250-4. doi: 10.5858/arpa.2013-0448-RS. PMID: 25171711
Horská A, Farage L, Bibat G, Nagae LM, Kaufmann WE, Barker PB, Naidu S
Ann Neurol 2009 Jan;65(1):90-7. doi: 10.1002/ana.21562. PMID: 19194883Free PMC Article
Powers JM, Moser HW
Brain Pathol 1998 Jan;8(1):101-20. doi: 10.1111/j.1750-3639.1998.tb00139.x. PMID: 9458170Free PMC Article

Recent clinical studies

Etiology

Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, Zetterberg H, Stomrud E, Ashton NJ, Blennow K, Hansson O
Brain 2021 Dec 16;144(11):3505-3516. doi: 10.1093/brain/awab223. PMID: 34259835Free PMC Article
Sharma P, Sharma A, Fayaz F, Wakode S, Pottoo FH
Curr Top Med Chem 2020;20(9):770-781. doi: 10.2174/1568026620666200228095553. PMID: 32108008
Rosenberg RN, Lambracht-Washington D, Yu G, Xia W
JAMA Neurol 2016 Jul 1;73(7):867-74. doi: 10.1001/jamaneurol.2016.0301. PMID: 27135718Free PMC Article
Olejniczak M, Urbanek MO, Krzyzosiak WJ
Mediators Inflamm 2015;2015:873860. Epub 2015 Mar 22 doi: 10.1155/2015/873860. PMID: 25873774Free PMC Article
Hernandez F, Lucas JJ, Avila J
J Alzheimers Dis 2013;33 Suppl 1:S141-4. doi: 10.3233/JAD-2012-129025. PMID: 22710914

Diagnosis

Gobom J, Brinkmalm A, Brinkmalm G, Blennow K, Zetterberg H
Mol Cell Proteomics 2024 Feb;23(2):100721. Epub 2024 Jan 20 doi: 10.1016/j.mcpro.2024.100721. PMID: 38246483
Carroll LS, Massey TH, Wardle M, Peall KJ
Tremor Other Hyperkinet Mov (N Y) 2018;8:577. Epub 2018 Oct 1 doi: 10.7916/D81N9HST. PMID: 30410817Free PMC Article
Iwasaki Y
Neuropathology 2017 Apr;37(2):174-188. Epub 2016 Dec 28 doi: 10.1111/neup.12355. PMID: 28028861
Butterworth RF
Handb Clin Neurol 2014;125:589-602. doi: 10.1016/B978-0-444-62619-6.00034-3. PMID: 25307598
Pusateri A, Margo CE
Arch Pathol Lab Med 2014 Sep;138(9):1250-4. doi: 10.5858/arpa.2013-0448-RS. PMID: 25171711

Therapy

Gopar-Cuevas Y, Saucedo-Cardenas O, Loera-Arias MJ, Montes-de-Oca-Luna R, Rodriguez-Rocha H, Garcia-Garcia A
Mol Neurobiol 2023 Dec;60(12):7253-7273. Epub 2023 Aug 5 doi: 10.1007/s12035-023-03530-5. PMID: 37542649
Jayanthi S, Daiwile AP, Cadet JL
Exp Neurol 2021 Oct;344:113795. Epub 2021 Jun 26 doi: 10.1016/j.expneurol.2021.113795. PMID: 34186102Free PMC Article
Guan J
Recent Pat CNS Drug Discov 2008 Jun;3(2):112-27. doi: 10.2174/157488908784534630. PMID: 18537771
Wersinger C, Sidhu A
Curr Med Chem 2006;13(5):591-602. doi: 10.2174/092986706776055760. PMID: 16515523
Seiler N
Neurochem Int 2002 Aug-Sep;41(2-3):189-207. doi: 10.1016/s0197-0186(02)00041-4. PMID: 12020619

Prognosis

Parker CA, Nutt DJ, Tyacke RJ
Int J Mol Sci 2023 Jun 6;24(12) doi: 10.3390/ijms24129787. PMID: 37372936Free PMC Article
Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, Zetterberg H, Stomrud E, Ashton NJ, Blennow K, Hansson O
Brain 2021 Dec 16;144(11):3505-3516. doi: 10.1093/brain/awab223. PMID: 34259835Free PMC Article
Rivera-Zengotita M, Yachnis AT
Adv Anat Pathol 2012 Jul;19(4):239-49. doi: 10.1097/PAP.0b013e31825c6a04. PMID: 22692287
Wersinger C, Sidhu A
Curr Med Chem 2006;13(5):591-602. doi: 10.2174/092986706776055760. PMID: 16515523
Seiler N
Neurochem Int 2002 Aug-Sep;41(2-3):189-207. doi: 10.1016/s0197-0186(02)00041-4. PMID: 12020619

Clinical prediction guides

Biscetti L, Cresta E, Cupini LM, Calabresi P, Sarchielli P
Neurobiol Dis 2023 May;180:106072. Epub 2023 Mar 11 doi: 10.1016/j.nbd.2023.106072. PMID: 36907522
Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, Zetterberg H, Stomrud E, Ashton NJ, Blennow K, Hansson O
Brain 2021 Dec 16;144(11):3505-3516. doi: 10.1093/brain/awab223. PMID: 34259835Free PMC Article
Schwabenland M, Salié H, Tanevski J, Killmer S, Lago MS, Schlaak AE, Mayer L, Matschke J, Püschel K, Fitzek A, Ondruschka B, Mei HE, Boettler T, Neumann-Haefelin C, Hofmann M, Breithaupt A, Genc N, Stadelmann C, Saez-Rodriguez J, Bronsert P, Knobeloch KP, Blank T, Thimme R, Glatzel M, Prinz M, Bengsch B
Immunity 2021 Jul 13;54(7):1594-1610.e11. Epub 2021 Jun 9 doi: 10.1016/j.immuni.2021.06.002. PMID: 34174183Free PMC Article
Iwasaki Y
Neuropathology 2017 Apr;37(2):174-188. Epub 2016 Dec 28 doi: 10.1111/neup.12355. PMID: 28028861
Rosenberg RN, Lambracht-Washington D, Yu G, Xia W
JAMA Neurol 2016 Jul 1;73(7):867-74. doi: 10.1001/jamaneurol.2016.0301. PMID: 27135718Free PMC Article

Recent systematic reviews

Evers J, Lowery M
Oper Neurosurg (Hagerstown) 2021 Jan 13;20(2):131-140. doi: 10.1093/ons/opaa326. PMID: 33074305
Rouvroye MD, Zis P, Van Dam AM, Rozemuller AJM, Bouma G, Hadjivassiliou M
Nutrients 2020 Mar 20;12(3) doi: 10.3390/nu12030822. PMID: 32244870Free PMC Article
Ostergaard PJ, Jensen MB
Int J Neurosci 2013 Jul;123(7):439-43. Epub 2013 Feb 11 doi: 10.3109/00207454.2013.765421. PMID: 23311713Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...